value of money in cancer - imrt as a case study jean h.e. yong, masc pharmacoeconomics research...
TRANSCRIPT
![Page 1: Value of Money in Cancer - IMRT as a case study Jean H.E. Yong, MASc Pharmacoeconomics Research Unit, Cancer Care Ontario Canadian Centre for Applied Research](https://reader035.vdocuments.us/reader035/viewer/2022062322/56649e2a5503460f94b18465/html5/thumbnails/1.jpg)
Value of Money in Cancer- IMRT as a case studyJean H.E. Yong, MAScPharmacoeconomics Research Unit, Cancer Care OntarioCanadian Centre for Applied Research in Cancer Control Applied Health Research Centre, St. Michael’s Hospital
![Page 2: Value of Money in Cancer - IMRT as a case study Jean H.E. Yong, MASc Pharmacoeconomics Research Unit, Cancer Care Ontario Canadian Centre for Applied Research](https://reader035.vdocuments.us/reader035/viewer/2022062322/56649e2a5503460f94b18465/html5/thumbnails/2.jpg)
Key messages It is important to consider Value for Money when planning and
coordinating cancer care Assessing value for money is not difficult, but needs to be relevant to
the context Let’s try to provide value for money every step along the cancer
journey
![Page 3: Value of Money in Cancer - IMRT as a case study Jean H.E. Yong, MASc Pharmacoeconomics Research Unit, Cancer Care Ontario Canadian Centre for Applied Research](https://reader035.vdocuments.us/reader035/viewer/2022062322/56649e2a5503460f94b18465/html5/thumbnails/3.jpg)
![Page 4: Value of Money in Cancer - IMRT as a case study Jean H.E. Yong, MASc Pharmacoeconomics Research Unit, Cancer Care Ontario Canadian Centre for Applied Research](https://reader035.vdocuments.us/reader035/viewer/2022062322/56649e2a5503460f94b18465/html5/thumbnails/4.jpg)
Value for money We want to buy as much health as possible But, we have limited resources Economics:
How much does something cost? What do we get for what we pay?
Cost-effectiveness analysis
![Page 5: Value of Money in Cancer - IMRT as a case study Jean H.E. Yong, MASc Pharmacoeconomics Research Unit, Cancer Care Ontario Canadian Centre for Applied Research](https://reader035.vdocuments.us/reader035/viewer/2022062322/56649e2a5503460f94b18465/html5/thumbnails/5.jpg)
Value for money in Cancer
Data: The Center for Evaluation of Value and Risk in Health, CEA Registry
![Page 6: Value of Money in Cancer - IMRT as a case study Jean H.E. Yong, MASc Pharmacoeconomics Research Unit, Cancer Care Ontario Canadian Centre for Applied Research](https://reader035.vdocuments.us/reader035/viewer/2022062322/56649e2a5503460f94b18465/html5/thumbnails/6.jpg)
Intensity-Modulated Radiation Therapy (IMRT) Introducing IMRT across Ontario Which disease sites? Is IMRT good value for money? Can we afford it?
Picture: Radiation Medical Group
![Page 7: Value of Money in Cancer - IMRT as a case study Jean H.E. Yong, MASc Pharmacoeconomics Research Unit, Cancer Care Ontario Canadian Centre for Applied Research](https://reader035.vdocuments.us/reader035/viewer/2022062322/56649e2a5503460f94b18465/html5/thumbnails/7.jpg)
![Page 8: Value of Money in Cancer - IMRT as a case study Jean H.E. Yong, MASc Pharmacoeconomics Research Unit, Cancer Care Ontario Canadian Centre for Applied Research](https://reader035.vdocuments.us/reader035/viewer/2022062322/56649e2a5503460f94b18465/html5/thumbnails/8.jpg)
Clinically localized disease
Biochemical failure
Metastasis
Dead
Localized prostate cancer
![Page 9: Value of Money in Cancer - IMRT as a case study Jean H.E. Yong, MASc Pharmacoeconomics Research Unit, Cancer Care Ontario Canadian Centre for Applied Research](https://reader035.vdocuments.us/reader035/viewer/2022062322/56649e2a5503460f94b18465/html5/thumbnails/9.jpg)
No toxicity Biochemical failure
Metastasis
Dead
Grade 2 GI toxicity
Grade 3 GI toxicity
![Page 10: Value of Money in Cancer - IMRT as a case study Jean H.E. Yong, MASc Pharmacoeconomics Research Unit, Cancer Care Ontario Canadian Centre for Applied Research](https://reader035.vdocuments.us/reader035/viewer/2022062322/56649e2a5503460f94b18465/html5/thumbnails/10.jpg)
IMRT vs. 3D-CRT in prostate cancer IMRT CRT Incremental
Radiation treatment cost $14,520 $13,501 $1,019
Radiotherapy toxicity cost $106 $508 $(402)
Total cost (discounted at 5%) $60,138 $59,518 $621
Life-years gained (discounted at 5%) 8.257 8.257 0.000
QALYs gained (discounted at 5%) 6.085 6.062 0.023
Incremental cost per QALY gained $26,768
![Page 11: Value of Money in Cancer - IMRT as a case study Jean H.E. Yong, MASc Pharmacoeconomics Research Unit, Cancer Care Ontario Canadian Centre for Applied Research](https://reader035.vdocuments.us/reader035/viewer/2022062322/56649e2a5503460f94b18465/html5/thumbnails/11.jpg)
Sensitivity analysis Results were sensitive to the disease control assumption and
treatment cost difference When IMRT is delivered at a higher dose than CRT, it is cost saving
and is more effective When we add Volumetric Modulated Arc Therapy to IMRT, IMRT
has shorter treatment time than CRT and becomes cost saving We estimated cost of IMRT for a mature program. In a start-up
program scenario, IMRT costs $279,850 per QALY.
![Page 12: Value of Money in Cancer - IMRT as a case study Jean H.E. Yong, MASc Pharmacoeconomics Research Unit, Cancer Care Ontario Canadian Centre for Applied Research](https://reader035.vdocuments.us/reader035/viewer/2022062322/56649e2a5503460f94b18465/html5/thumbnails/12.jpg)
IMRT vs. 2D-RT in head and neck cancers Compared with 2D-RT, IMRT reduces xerostomia and improves
quality of life IMRT is less expensive than CRT
saves $1100 per patient IMRT takes longer to plan but less time to deliver
Results are most sensitive to the cost difference between treatment In a start up program scenario: $162,000 per QALY
![Page 13: Value of Money in Cancer - IMRT as a case study Jean H.E. Yong, MASc Pharmacoeconomics Research Unit, Cancer Care Ontario Canadian Centre for Applied Research](https://reader035.vdocuments.us/reader035/viewer/2022062322/56649e2a5503460f94b18465/html5/thumbnails/13.jpg)
Discussion Results are specific to the research questions
Not generalizable to other indications Specific to the comparator Radiotherapy costs vary across countries
Validate model Literature review and sensitivity analysis
![Page 14: Value of Money in Cancer - IMRT as a case study Jean H.E. Yong, MASc Pharmacoeconomics Research Unit, Cancer Care Ontario Canadian Centre for Applied Research](https://reader035.vdocuments.us/reader035/viewer/2022062322/56649e2a5503460f94b18465/html5/thumbnails/14.jpg)
Success Factors An in house health economics unit Effective partnerships with many stakeholders
Academics Community providers
Evaluation part of an implementation strategy
![Page 15: Value of Money in Cancer - IMRT as a case study Jean H.E. Yong, MASc Pharmacoeconomics Research Unit, Cancer Care Ontario Canadian Centre for Applied Research](https://reader035.vdocuments.us/reader035/viewer/2022062322/56649e2a5503460f94b18465/html5/thumbnails/15.jpg)
Cancer journey
![Page 16: Value of Money in Cancer - IMRT as a case study Jean H.E. Yong, MASc Pharmacoeconomics Research Unit, Cancer Care Ontario Canadian Centre for Applied Research](https://reader035.vdocuments.us/reader035/viewer/2022062322/56649e2a5503460f94b18465/html5/thumbnails/16.jpg)
Value for money in Cancer
Data: The Center for Evaluation of Value and Risk in Health, CEA Registry
313 studies (2004-2010)
![Page 17: Value of Money in Cancer - IMRT as a case study Jean H.E. Yong, MASc Pharmacoeconomics Research Unit, Cancer Care Ontario Canadian Centre for Applied Research](https://reader035.vdocuments.us/reader035/viewer/2022062322/56649e2a5503460f94b18465/html5/thumbnails/17.jpg)
Key messages It is important to consider Value for Money when planning and
coordinating cancer care Assessing value for money is not difficult, but needs to be relevant to
the context Let’s try to provide value for money every step along the cancer
journey
![Page 18: Value of Money in Cancer - IMRT as a case study Jean H.E. Yong, MASc Pharmacoeconomics Research Unit, Cancer Care Ontario Canadian Centre for Applied Research](https://reader035.vdocuments.us/reader035/viewer/2022062322/56649e2a5503460f94b18465/html5/thumbnails/18.jpg)
Acknowledgements Dr. Jeffrey Hoch & Jaclyn Beca Cancer Care Ontario Community practitioners
Radiation oncologists, physicists, therapists Academic collaborators
Drs. Tom McGowan and Murray Krahn IMRT Indications Expert Panel
Drs. Brian O’Sullivan and Glenn Bauman
Ontario Ministry of Health and Long-Term Care
![Page 19: Value of Money in Cancer - IMRT as a case study Jean H.E. Yong, MASc Pharmacoeconomics Research Unit, Cancer Care Ontario Canadian Centre for Applied Research](https://reader035.vdocuments.us/reader035/viewer/2022062322/56649e2a5503460f94b18465/html5/thumbnails/19.jpg)
Thank [email protected]
![Page 20: Value of Money in Cancer - IMRT as a case study Jean H.E. Yong, MASc Pharmacoeconomics Research Unit, Cancer Care Ontario Canadian Centre for Applied Research](https://reader035.vdocuments.us/reader035/viewer/2022062322/56649e2a5503460f94b18465/html5/thumbnails/20.jpg)
Cancer Care in Canada Universal health care Limited access to
interventions that are not covered by public payers Public health agency Provincial cancer agencies Provincial drug plans Hospitals
![Page 21: Value of Money in Cancer - IMRT as a case study Jean H.E. Yong, MASc Pharmacoeconomics Research Unit, Cancer Care Ontario Canadian Centre for Applied Research](https://reader035.vdocuments.us/reader035/viewer/2022062322/56649e2a5503460f94b18465/html5/thumbnails/21.jpg)
Activity-based costing